Leerink Partners on Viridian Therapeutic (VRDN): 'encouraged' by response rate, but efficacy below investor expectations
March 30, 2026 8:41 AM
Leerink Partners analyst Thomas Smith reiterated an Outperform rating and $50.00 price target on Viridian Therapeutic (NASDAQ: VRDN)The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
